## Marie-Odile Krebs

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4653321/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 2022, 604, 502-508.	27.8	929
2	Subthalamic Nucleus Stimulation in Severe Obsessive–Compulsive Disorder. New England Journal of Medicine, 2008, 359, 2121-2134.	27.0	829
3	Clinical spectrum of CADASIL: a study of 7 families. Lancet, The, 1995, 346, 934-939.	13.7	670
4	Altering the course of schizophrenia: progress and perspectives. Nature Reviews Drug Discovery, 2016, 15, 485-515.	46.4	410
5	Increased exonic de novo mutation rate in individuals with schizophrenia. Nature Genetics, 2011, 43, 860-863.	21.4	392
6	De novo mutations in the gene encoding the synaptic scaffolding protein <i>SHANK3</i> in patients ascertained for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 7863-7868.	7.1	361
7	Glutamatergic Control of Dopamine Release in the Rat Striatum: Evidence for Presynaptic N-Methyl-D-Aspartate Receptors on Dopaminergic Nerve Terminals. Journal of Neurochemistry, 1991, 56, 81-85.	3.9	341
8	Prevention of Psychosis. JAMA Psychiatry, 2020, 77, 755.	11.0	287
9	Mutations in <i>SYNGAP1</i> in Autosomal Nonsyndromic Mental Retardation. New England Journal of Medicine, 2009, 360, 599-605.	27.0	282
10	The Role of the Cerebellum in Schizophrenia: an Update of Clinical, Cognitive, and Functional Evidences. Schizophrenia Bulletin, 2007, 34, 155-172.	4.3	256
11	Burnout in medical students before residency: A systematic review and meta-analysis. European Psychiatry, 2019, 55, 36-42.	0.2	248
12	Truncating mutations in NRXN2 and NRXN1 in autism spectrum disorders and schizophrenia. Human Genetics, 2011, 130, 563-573.	3.8	237
13	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. Schizophrenia Bulletin, 2014, 40, 729-736.	4.3	229
14	Direct Measure of the De Novo Mutation Rate in Autism and Schizophrenia Cohorts. American Journal of Human Genetics, 2010, 87, 316-324.	6.2	222
15	Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Translational Psychiatry, 2011, 1, e55-e55.	4.8	205
16	De Novo Mutations in FOXP1 in Cases with Intellectual Disability, Autism, and Language Impairment. American Journal of Human Genetics, 2010, 87, 671-678.	6.2	200
17	Brain Derived Neurotrophic Factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Molecular Psychiatry, 2000, 5, 558-562.	7.9	170
18	De Novo SYNGAP1 Mutations in Nonsyndromic Intellectual Disability and Autism. Biological Psychiatry, 2011, 69, 898-901.	1.3	164

#	Article	IF	CITATIONS
19	Progressive Loss of Dopaminergic Neurons in the Ventral Midbrain of Adult Mice Heterozygote for Engrailed1. Journal of Neuroscience, 2007, 27, 1063-1071.	3.6	148
20	Substance abuse and suicidality in schizophrenia: a common risk factor linked to impulsivity. Psychiatry Research, 2001, 102, 65-72.	3.3	135
21	Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. Translational Psychiatry, 2015, 5, e601-e601.	4.8	134
22	Validation and factorial structure of a standardized neurological examination assessing neurological soft signs in schizophrenia. Schizophrenia Research, 2000, 45, 245-260.	2.0	133
23	Peri-pubertal maturation after developmental disturbance: A model for psychosis onset in the rat. Neuroscience, 2006, 143, 395-405.	2.3	130
24	ls Substance Abuse in Schizophrenia Related to Impulsivity, Sensation Seeking, or Anhedonia?. American Journal of Psychiatry, 2001, 158, 492-494.	7.2	124
25	Working memory deficits in adult rats after prenatal disruption of neurogenesis. Behavioural Pharmacology, 2004, 15, 287-292.	1.7	117
26	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biological Psychiatry, 2022, 91, 313-327.	1.3	114
27	Admixture analysis of age at onset in obsessive–compulsive disorder. Psychological Medicine, 2005, 35, 237-243.	4.5	113
28	Decrease of Prefrontal Metabolism After Subthalamic Stimulation in Obsessive-Compulsive Disorder: A Positron Emission Tomography Study. Biological Psychiatry, 2010, 68, 1016-1022.	1.3	111
29	Long-term consequences of adolescent cannabinoid exposure in adult psychopathology. Frontiers in Neuroscience, 2014, 8, 361.	2.8	108
30	Absence of association between a polymorphic GGC repeat in the 5′ untranslated region of the reelin gene and autism. Molecular Psychiatry, 2002, 7, 801-804.	7.9	96
31	Frequency and transmission of glutamate receptors GRIK2 and GRIK3 polymorphisms in patients with obsessive compulsive disorder. NeuroReport, 2004, 15, 699-702.	1.2	82
32	(AAT)n repeat in the cannabinoid receptor gene (CNR1): association with cocaine addiction in an African-Caribbean population. Pharmacogenomics Journal, 2006, 6, 126-130.	2.0	81
33	Neurological and morphological anomalies and the genetic liability to schizophrenia: a composite phenotype. Schizophrenia Research, 2004, 67, 23-31.	2.0	78
34	Confidence and psychosis: a neuro-computational account of contingency learning disruption by NMDA blockade. Molecular Psychiatry, 2016, 21, 946-955.	7.9	77
35	One-carbon metabolism and schizophrenia: current challenges and future directions. Trends in Molecular Medicine, 2009, 15, 562-570.	6.7	76
36	Salivary cortisol in early psychosis: New findings and meta-analysis. Psychoneuroendocrinology, 2016, 63, 262-270.	2.7	76

#	Article	IF	CITATIONS
37	Dopamine D3 receptor gene variants and substance abuse in schizophrenia. Molecular Psychiatry, 1998, 3, 337-341.	7.9	75
38	Association between the dopamine receptor D4 (DRD4) gene and obsessiveâ€compulsive disorder. American Journal of Medical Genetics Part A, 2003, 116B, 55-59.	2.4	74
39	Minor physical anomalies in patients with schizophrenia and their parents: prevalence and pattern of craniofacial abnormalities. Psychiatry Research, 2004, 125, 21-28.	3.3	74
40	Long-term cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison. Psychopharmacology, 2013, 225, 781-790.	3.1	74
41	Epigenetics and depression: current challenges and new therapeutic options. Current Opinion in Psychiatry, 2010, 23, 588-592.	6.3	72
42	Cortex Morphology in First-Episode Psychosis Patients With Neurological Soft Signs. Schizophrenia Bulletin, 2013, 39, 820-829.	4.3	70
43	Chronic cannabinoid exposure during adolescence leads to long-term structural and functional changes in the prefrontal cortex. European Neuropsychopharmacology, 2016, 26, 55-64.	0.7	66
44	CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis. Addiction Biology, 2011, 16, 1-6.	2.6	65
45	Phenotypic continuum between autism and schizophrenia: Evidence from the Movie for the Assessment of Social Cognition (MASC). Schizophrenia Research, 2017, 185, 161-166.	2.0	65
46	Glycine potentiates the NMDA-induced release of dopamine through a strychnine-insensitive site in the rat striatum. European Journal of Pharmacology, 1989, 166, 567-570.	3.5	61
47	Impulsivity and sensation seeking in alcohol abusing patients with schizophrenia. Frontiers in Psychiatry, 2010, 1, 135.	2.6	61
48	Correlations of cerebello-thalamo-prefrontal structure and neurological soft signs in patients with first-episode psychosis. Acta Psychiatrica Scandinavica, 2011, 123, 451-458.	4.5	59
49	Neurological soft-signs and minor physical anomalies in schizophrenia: differential transmission within families. Schizophrenia Research, 2003, 63, 181-187.	2.0	57
50	Development of Proteomic Prediction Models for Transition to Psychotic Disorder in the Clinical High-Risk State and Psychotic Experiences in Adolescence. JAMA Psychiatry, 2021, 78, 77.	11.0	57
51	Maternal transmission disequilibrium of the glutamate receptor GRIK2 in schizophrenia. NeuroReport, 2004, 15, 1987-1991.	1.2	56
52	Limbic versus cognitive target for deep brain stimulation in treatment-resistant depression: Accumbens more promising than caudate. European Neuropsychopharmacology, 2014, 24, 1229-1239.	0.7	56
53	Methylomic changes during conversion to psychosis. Molecular Psychiatry, 2017, 22, 512-518.	7.9	56
54	Age at onset of schizophrenia: interaction between brain-derived neurotrophic factor and dopamine D3 receptor gene variants. NeuroReport, 2005, 16, 1407-1410.	1.2	53

#	Article	IF	CITATIONS
55	Interaction of dopamine D1 with NMDA NR1 receptors in rat prefrontal cortex. European Neuropsychopharmacology, 2009, 19, 296-304.	0.7	50
56	A Serious Game to Improve Cognitive Functions in Schizophrenia: A Pilot Study. Frontiers in Psychiatry, 2016, 7, 64.	2.6	48
57	Correlation between clinical syndromes and neuropsychological tasks in unmedicated patients with recent onset schizophrenia. Psychiatry Research, 2002, 113, 83-92.	3.3	47
58	Behavioral Perturbations After Prenatal Neurogenesis Disturbance in Female Rat. Neurotoxicity Research, 2009, 15, 311-320.	2.7	47
59	Support for the association between the rare functional variant I425V of the serotonin transporter gene and susceptibility to obsessive compulsive disorder. Molecular Psychiatry, 2005, 10, 1059-1061.	7.9	46
60	Altered semantic but not phonological verbal fluency in young help-seeking individuals with ultra high risk of psychosis. Schizophrenia Research, 2010, 123, 53-58.	2.0	46
61	Age-Related Changes in the Functional Network Underlying Specific and General Autobiographical Memory Retrieval: A Pivotal Role for the Anterior Cingulate Cortex. PLoS ONE, 2013, 8, e82385.	2.5	46
62	Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia. Journal of Psychiatric Research, 2005, 39, 391-398.	3.1	44
63	De Novo Truncating Mutation in Kinesin 17 Associated with Schizophrenia. Biological Psychiatry, 2010, 68, 649-656.	1.3	43
64	The 5-HTTLPR polymorphism, impulsivity and suicide behavior in euthymic bipolar patients. Journal of Affective Disorders, 2011, 133, 221-226.	4.1	43
65	Local GABAergic regulation of the N-methyl-d-aspartate-evoked release of dopamine is more prominent in striosomes than in matrix of the rat striatum. Neuroscience, 1993, 57, 249-260.	2.3	42
66	Amyloid precursor protein cytoplasmic domain antagonizes reelin neurite outgrowth inhibition of hippocampal neurons. Neurobiology of Aging, 2008, 29, 542-553.	3.1	42
67	Deviations in cortex sulcation associated with visual hallucinations in schizophrenia. Molecular Psychiatry, 2015, 20, 1101-1107.	7.9	42
68	Perinatal Exposure to Environmental Endocrine Disruptors in the Emergence of Neurodevelopmental Psychiatric Diseases: A Systematic Review. International Journal of Environmental Research and Public Health, 2019, 16, 1318.	2.6	42
69	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. Biological Psychiatry, 2021, 89, 288-297.	1.3	42
70	Population-based and family-based association study of 5′UTR polymorphism of the reelin gene and schizophrenia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 137B, 51-55.	1.7	40
71	Polymorphisms TaqI A of the DRD2, Ball of the DRD3, exon III repeat of the DRD4, and 3′ UTR VNTR of the DAT: Association with childhood ADHD in male African aribbean cocaine dependents?. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 1034-1041.	1.7	39
72	Association of Disrupted in Schizophrenia 1 (DISC1) missense variants with ultra-resistant schizophrenia. Pharmacogenomics Journal, 2011, 11, 267-273.	2.0	39

#	Article	IF	CITATIONS
73	Neurological soft signs and schizotypal dimensions in unaffected siblings of patients with schizophrenia. Psychiatry Research, 2010, 175, 22-26.	3.3	38
74	European college of neuropsychopharmacology network on the prevention of mental disorders and mental health promotion (ECNP PMD-MHP). European Neuropsychopharmacology, 2019, 29, 1301-1311.	0.7	38
75	Conscious and unconscious performance monitoring: Evidence from patients with schizophrenia. NeuroImage, 2017, 144, 153-163.	4.2	37
76	High-Frequency Neuronavigated rTMS in Auditory Verbal Hallucinations: A Pilot Double-Blind Controlled Study in Patients With Schizophrenia. Schizophrenia Bulletin, 2018, 44, 505-514.	4.3	37
77	Exposure to cannabinoids can lead to persistent cognitive and psychiatric disorders. European Journal of Pain, 2019, 23, 1225-1233.	2.8	37
78	Neurological soft signs in patients with schizophrenia and their unaffected siblings: frequency and correlates in two ethnic and socioeconomic distinct populations. European Archives of Psychiatry and Clinical Neuroscience, 2009, 259, 218-226.	3.2	36
79	Real world referencing and schizophrenia: Are we experiencing the same reality?. Neuropsychologia, 2010, 48, 2922-2930.	1.6	35
80	Clinical features of panic attacks in schizophrenia. European Psychiatry, 2001, 16, 349-353.	0.2	34
81	Memory-guided saccade abnormalities in schizophrenic patients and their healthy, full biological siblings. Psychological Medicine, 2008, 38, 861-870.	4.5	34
82	Episodic memory and self-reference via semantic autobiographical memory: insights from an fMRI study in younger and older adults. Frontiers in Behavioral Neuroscience, 2014, 8, 449.	2.0	34
83	Genetic variability in scaffolding proteins and risk for schizophrenia and autism-spectrum disorders: a systematic review. Journal of Psychiatry and Neuroscience, 2018, 43, 223-244.	2.4	34
84	"A circle and a triangle dancing together― Alteration of social cognition in schizophrenia compared to autism spectrum disorders. Schizophrenia Research, 2019, 210, 94-100.	2.0	34
85	Histamine H2 receptor gene variants: lack of association with schizophrenia. Molecular Psychiatry, 2000, 5, 159-164.	7.9	33
86	Neuronal activity correlated with checking behaviour in the subthalamic nucleus of patients with obsessive–compulsive disorder. Brain, 2013, 136, 304-317.	7.6	33
87	Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A). Journal of Affective Disorders, 2022, 299, 367-376.	4.1	33
88	New evidences of gene and environment interactions affecting prenatal neurodevelopment in schizophrenia-spectrum disorders: A family dermatoglyphic study. Schizophrenia Research, 2008, 103, 209-217.	2.0	31
89	Sensory dysfunction is correlated to cerebellar volume reduction in early schizophrenia. Schizophrenia Research, 2007, 91, 266-269.	2.0	30
90	Neuropathological and Reelin Deficiencies in the Hippocampal Formation of Rats Exposed to MAM; Differences and Similarities with Schizophrenia. PLoS ONE, 2010, 5, e10291.	2.5	30

#	Article	IF	CITATIONS
91	Understanding the impact of persistent symptoms in schizophrenia: Cross-sectional findings from the Pattern study. Schizophrenia Research, 2015, 169, 234-240.	2.0	29
92	Saccadic eye movements as markers of schizophrenia spectrum: Exploration in at-risk mental states. Schizophrenia Research, 2017, 181, 30-37.	2.0	29
93	Genetic vulnerability to drug abuse. European Psychiatry, 2000, 15, 109-114.	0.2	28
94	Impairment of predictive saccades in schizophrenia. NeuroReport, 2001, 12, 465-469.	1.2	28
95	"Who is talking to me?―— Self–other attribution of auditory hallucinations and sulcation of the right temporoparietal junction. Schizophrenia Research, 2015, 169, 95-100.	2.0	28
96	The role of BDNF genetic polymorphisms in bipolar disorder with psychiatric comorbidities. Journal of Affective Disorders, 2011, 131, 307-311.	4.1	27
97	Confirmation of the factorial structure of temperamental autoquestionnaire TEMPS-A in non-clinical young adults and relation to current state of anxiety, depression and to schizotypal traits. Journal of Affective Disorders, 2011, 131, 37-44.	4.1	27
98	Nicotine use in schizophrenia and disinhibition. Psychiatry Research, 2004, 128, 229-234.	3.3	26
99	Factoring neurotrophins into a neurite-based pathophysiological model of schizophrenia. Progress in Neurobiology, 2011, 94, 77-90.	5.7	26
100	Altered cortical processing of motor inhibition in schizophrenia. Cortex, 2016, 85, 1-12.	2.4	26
101	Understanding the course of persistent symptoms in schizophrenia: Longitudinal findings from the pattern study. Psychiatry Research, 2018, 267, 56-62.	3.3	26
102	Don't be Too Strict with Yourself! Rigid Negative Self-Representation in Healthy Subjects Mimics the Neurocognitive Profile of Depression for Autobiographical Memory. Frontiers in Behavioral Neuroscience, 2013, 7, 41.	2.0	25
103	Exploring and visualizing multidimensional data in translational research platforms. Briefings in Bioinformatics, 2016, 18, bbw080.	6.5	25
104	IMAGING STUDY: Exposure to smoking cues during an emotion recognition task can modulate limbic fMRI activation in cigarette smokers. Addiction Biology, 2009, 14, 469-477.	2.6	24
105	Variable individual sensitivity to cannabis in patients with schizophrenia. International Journal of Neuropsychopharmacology, 2010, 13, 1145-1154.	2.1	24
106	The C'JAAD: a French team for early intervention in psychosis in Paris. Microbial Biotechnology, 2018, 12, 243-249.	1.7	24
107	Longitudinal Analyses of Blood Transcriptome During Conversion to Psychosis. Schizophrenia Bulletin, 2019, 45, 247-255.	4.3	24
108	Apolipoprotein E in schizophrenia: A French association study and metaâ€analysis. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2003, 119B, 18-23.	1.7	23

#	Article	IF	CITATIONS
109	Validity of the CAGE questionnaire in schizophrenic patients with alcohol abuse and dependence. Schizophrenia Research, 2006, 81, 151-155.	2.0	23
110	Clozapine-Induced Serositis. Clinical Neuropharmacology, 2009, 32, 219-223.	0.7	23
111	Family-based association study of common variants, rare mutation study and epistatic interaction detection in HDAC genes in schizophrenia. Schizophrenia Research, 2014, 160, 97-103.	2.0	23
112	Association of Adverse Outcomes With Emotion Processing and Its Neural Substrate in Individuals at Clinical High Risk for Psychosis. JAMA Psychiatry, 2020, 77, 190.	11.0	23
113	Primary prevention of depression: An umbrella review of controlled interventions. Journal of Affective Disorders, 2021, 294, 957-970.	4.1	23
114	Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings. Molecular Psychiatry, 2021, 26, 4529-4543.	7.9	23
115	The French version of the validated short TEMPS-A: The temperament evaluation of Memphis, Pisa, Paris and San Diego. Journal of Affective Disorders, 2006, 96, 271-273.	4.1	22
116	Impulsivity and sensation seeking in cannabis abusing patients with schizophrenia. Schizophrenia Research, 2010, 123, 278-280.	2.0	22
117	Data mining based Bayesian networks for best classification. Computational Statistics and Data Analysis, 2006, 51, 1278-1292.	1.2	21
118	Neurological Soft Signs in OCD Patients With Early Age at Onset, Versus Patients With Schizophrenia and Healthy Subjects. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 409-416.	1.8	21
119	Effect of antipsychotics on spontaneous hyperactivity and hypersensitivity to MK-801-induced hyperactivity in rats prenatally exposed to methylazoxymethanol. Journal of Psychopharmacology, 2011, 25, 822-835.	4.0	21
120	Diethylstilbestrol and risk of psychiatric disorders: A critical review and new insights. World Journal of Biological Psychiatry, 2012, 13, 84-95.	2.6	21
121	Impaired attentional modulation of sensorimotor control and cortical excitability in schizophrenia. Brain, 2019, 142, 2149-2164.	7.6	21
122	Neurological soft signs in nonâ€psychotic patients with cannabis dependence. Addiction Biology, 2013, 18, 214-221.	2.6	20
123	Polymorphisms of coding trinucleotide repeats of homeogenes in neurodevelopmental psychiatric disorders. Psychiatric Genetics, 2008, 18, 295-301.	1.1	19
124	Episodic memory and impairment of an early encoding process in schizophrenia Neuropsychology, 2010, 24, 101-108.	1.3	19
125	Gender differences of patients at-risk for psychosis regarding symptomatology, drug use, comorbidity and functioning $\hat{a} \in \mathbb{C}^{m}$ Results from the EU-GEI study. European Psychiatry, 2019, 59, 52-59.	0.2	19
126	Alterations in prefrontal glutamatergic and noradrenergic systems following MK-801 administration in rats prenatally exposed to methylazoxymethanol at gestational dayÂ17. Psychopharmacology, 2007, 192, 373-383.	3.1	18

#	Article	IF	CITATIONS
127	Progressive loss of dopaminergic neurons in the ventral midbrain of adult mice heterozygote for Engrailed1: A new genetic model for Parkinson's disease?. Parkinsonism and Related Disorders, 2008, 14, S107-S111.	2.2	18
128	Cognitive remediation therapy (CRT) benefits more to patients with schizophrenia with low initial memory performances. Disability and Rehabilitation, 2015, 37, 846-853.	1.8	18
129	Methylomic changes in individuals with psychosis, prenatally exposed to endocrine disrupting compounds: Lessons from diethylstilbestrol. PLoS ONE, 2017, 12, e0174783.	2.5	18
130	Association of Inflammation Genes with Alcohol Dependence/Abuse: A Systematic Review and a Meta-Analysis. European Addiction Research, 2011, 17, 146-153.	2.4	17
131	Mutation Burden of Rare Variants in Schizophrenia Candidate Genes. PLoS ONE, 2015, 10, e0128988.	2.5	17
132	Effects of atypical neuroleptics on alertness and visual orienting in stabilized schizophrenic patients: a preliminary study. International Journal of Neuropsychopharmacology, 2004, 7, 255-263.	2.1	16
133	Subjects at Ultra High Risk for psychosis have â€`heterogeneous' intellectual functioning profile: A multiple-case study. Schizophrenia Research, 2014, 152, 415-420.	2.0	16
134	Clinical, cognitive and neuroanatomical associations of serum NMDAR autoantibodies in people at clinical high risk for psychosis. Molecular Psychiatry, 2021, 26, 2590-2604.	7.9	16
135	Impaired saccadic adaptation in schizophrenic patients with high neurological soft sign scores. Psychiatry Research, 2012, 199, 12-18.	3.3	15
136	Investigation of rare variants in LRP1, KPNA1, ALS2CL and ZNF480 genes in schizophrenia patients reflects genetic heterogeneity of the disease. Behavioral and Brain Functions, 2013, 9, 9.	3.3	15
137	Reading impairment in schizophrenia: Dysconnectivity within the visual system. Neuropsychologia, 2014, 53, 187-196.	1.6	15
138	Cognitive control deficit in patients with first-episode schizophrenia is associated with complex deviations of early brain development. Journal of Psychiatry and Neuroscience, 2017, 42, 87-94.	2.4	15
139	Influence of polygenic risk scores for schizophrenia and resilience on the cognition of individuals at-risk for psychosis. Translational Psychiatry, 2021, 11, 518.	4.8	15
140	Hyperfrontality and hypoconnectivity during refreshing in schizophrenia. Psychiatry Research - Neuroimaging, 2013, 211, 226-233.	1.8	14
141	Oculomotricity and Neurological Soft Signs: Can we refine the endophenotype? A study in subjects belonging to the spectrum of schizophrenia. Psychiatry Research, 2017, 256, 490-497.	3.3	14
142	Transdifferentiation of Human Circulating Monocytes Into Neuronal-Like Cells in 20 Days and Without Reprograming. Frontiers in Molecular Neuroscience, 2018, 11, 323.	2.9	14
143	Epigenetic variability in conversion to psychosis: novel findings from an innovative longitudinal methylomic analysis. Translational Psychiatry, 2018, 8, 93.	4.8	14
144	Emotion Recognition and Adverse Childhood Experiences in Individuals at Clinical High Risk of Psychosis. Schizophrenia Bulletin, 2020, 46, 823-833.	4.3	14

#	Article	IF	CITATIONS
145	Deficient Grip Force Control in Schizophrenia: Behavioral and Modeling Evidence for Altered Motor Inhibition and Motor Noise. PLoS ONE, 2014, 9, e111853.	2.5	14
146	Comparing effects of perceptual and reflective repetition on subjective experience during later recognition memory. Consciousness and Cognition, 2008, 17, 753-764.	1.5	13
147	Correlates between neurological soft signs and saccadic parameters in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 676-681.	4.8	13
148	Non-cell-autonomous OTX2 transcription factor regulates anxiety-related behavior in the mouse. Molecular Psychiatry, 2021, 26, 6469-6480.	7.9	13
149	Cannabis Use and Schizophrenia. American Journal of Psychiatry, 2005, 162, 401-a-402.	7.2	12
150	Postnatal effect of embryonic neurogenesis disturbance on reelin level in organotypic cultures of rat hippocampus. Brain Research, 2006, 1097, 43-51.	2.2	12
151	Clozapine and long-acting injectable antipsychotic combination: A retrospective one-year mirror-image study. Schizophrenia Research, 2017, 188, 89-91.	2.0	12
152	Dysregulation of peripheral expression of the YWHA genes during conversion to psychosis. Scientific Reports, 2020, 10, 9863.	3.3	12
153	Manual Dexterity in Schizophrenia—A Neglected Clinical Marker?. Frontiers in Psychiatry, 2017, 8, 120.	2.6	11
154	Can the Positive and Negative Syndrome scale (PANSS) differentiate treatment-resistant from non-treatment-resistant schizophrenia? A factor analytic investigation based on data from the Pattern cohort study. Psychiatry Research, 2019, 276, 210-217.	3.3	11
155	Relationship between jumping to conclusions and clinical outcomes in people at clinical high-risk for psychosis. Psychological Medicine, 2022, 52, 1569-1577.	4.5	11
156	Dopamine-induced pruning in monocyte-derived-neuronal-like cells (MDNCs) from patients with schizophrenia. Molecular Psychiatry, 2022, 27, 2787-2802.	7.9	11
157	Inflexible information acquisition strategies mediate visuo-spatial reasoning in stabilized schizophrenia patients. World Journal of Biological Psychiatry, 2011, 12, 608-619.	2.6	10
158	Predicting the individual risk of psychosis conversion in at-risk mental state (ARMS): a multivariate model reveals the influence of nonpsychotic prodromal symptoms. European Child and Adolescent Psychiatry, 2020, 29, 1525-1535.	4.7	10
159	A polymorphism in the glutamate metabotropic receptor 7 is associated with cognitive deficits in the early phases of psychosis. Schizophrenia Research, 2022, 249, 56-62.	2.0	10
160	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. Schizophrenia Bulletin, 2021, 47, 1018-1028.	4.3	10
161	Verbal memory performance predicts remission and functional outcome in people at clinical high-risk for psychosis. Schizophrenia Research: Cognition, 2022, 28, 100222.	1.3	10
162	Association study of the trinucleotide repeat polymorphism within SMARCA2 and schizophrenia. BMC Genetics, 2006, 7, 34.	2.7	9

#	Article	IF	CITATIONS
163	Individual factors influencing the duration of untreated psychosis. Microbial Biotechnology, 2019, 13, 798-804.	1.7	9
164	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. Schizophrenia Bulletin, 2022, 48, 100-110.	4.3	9
165	Does bicuculline antagonize NMDA receptors? Further evidence in the rat striatum. Brain Research, 1994, 634, 345-348.	2.2	8
166	Health-related quality of life in outpatients with schizophrenia: factors that determine changes over time. Social Psychiatry and Psychiatric Epidemiology, 2018, 53, 239-248.	3.1	8
167	<p>Correlation of Health-Related Quality of Life in Clinically Stable Outpatients with Schizophrenia</p> . Neuropsychiatric Disease and Treatment, 2019, Volume 15, 3475-3486.	2.2	8
168	Predictive Modulation of Corticospinal Excitability and Implicit Encoding of Movement Probability in Schizophrenia. Schizophrenia Bulletin, 2019, 45, 1358-1366.	4.3	8
169	Common vs. Distinct Visuomotor Control Deficits in Autism Spectrum Disorder and Schizophrenia. Autism Research, 2020, 13, 885-896.	3.8	8
170	Attention and visual orienting in siblings, schizophrenic patients, and controls: Impairment in attentional disengagement. Journal of Clinical and Experimental Neuropsychology, 2010, 32, 449-454.	1.3	7
171	A step toward an objective quantification of subtle neurological signs in schizophrenia. Psychiatry Research, 2012, 198, 230-234.	3.3	7
172	Persistent Depersonalization/Derealization Disorder Induced by Synthetic Cannabinoids. American Journal of Psychiatry, 2016, 173, 839-840.	7.2	7
173	Paradoxical Improvement of Schizophrenic Symptoms by a Dopaminergic Agonist: An Example of Personalized Psychiatry in a Copy Number Variation–Carrying Patient. Biological Psychiatry, 2016, 80, e21-e23.	1.3	7
174	Predictive saccades are impaired in biological nonpsychotic siblings of schizophrenia patients. Journal of Psychiatry and Neuroscience, 2008, 33, 17-22.	2.4	7
175	Potential application as screening and drug designing tools of cytoarchitectural deficiencies present in three animal models of schizophrenia. Expert Opinion on Drug Discovery, 2009, 4, 257-278.	5.0	6
176	Self-reference recollection effect and its relation to theory of mind: An investigation in healthy controls and schizophrenia. Consciousness and Cognition, 2016, 42, 51-64.	1.5	6
177	Pre-training inter-rater reliability of clinical instruments in an international psychosis research project. Schizophrenia Research, 2020, 230, 104-107.	2.0	6
178	Neural noise and cortical inhibition in schizophrenia. Brain Stimulation, 2020, 13, 1298-1304.	1.6	6
179	Eye Movements in Psychiatry. Studies in Neuroscience, Psychology and Behavioral Economics, 2019, , 703-748.	0.3	6
180	Cerebellum development and schizophrenia: an association study of the human homeogene Engrailed 2. Psychiatry Research, 2004, 126, 93-98.	3.3	5

#	Article	IF	CITATIONS
181	Ultra-Resistant Schizophrenia Is Not Associated With the Multidrug-Resistant Transporter 1 (MDR1) Gene rs1045642 Variant. Journal of Clinical Psychopharmacology, 2011, 31, 236-238.	1.4	5
182	Détection et intervention précoceÂ: un nouveau paradigme. Annales Medico-Psychologiques, 2018, 176, 65-69.	0.4	5
183	One-year mirror-image study of the impact of olanzapine long-acting injection on healthcare resource utilization and costs in severe schizophrenia. Psychiatry Research, 2018, 270, 205-210.	3.3	5
184	Is cannabis responsible for early onset psychotic illnesses?. Neuropsychiatry, 2011, 1, 203-207.	0.4	4
185	Reliability and correlation of mixture cell correction in methylomic and transcriptomic blood data. BMC Research Notes, 2020, 13, 74.	1.4	4
186	A novel tablet-based application for assessment of manual dexterity and its components: a reliability and validity study in healthy subjects. Journal of NeuroEngineering and Rehabilitation, 2022, 19, 35.	4.6	4
187	Dysmaturational Longitudinal Epigenetic Aging During Transition to Psychosis. Schizophrenia Bulletin Open, 2022, 3, .	1.7	4
188	Future contributions on genetics. World Journal of Biological Psychiatry, 2005, 6, 49-55.	2.6	3
189	Stress, Cortisol and NR3C1 in At-Risk Individuals for Psychosis: A Mendelian Randomization Study. Frontiers in Psychiatry, 2020, 11, 680.	2.6	3
190	Specific pattern of attentional changes in impulsive individuals. Cognitive Neuropsychiatry, 2006, 11, 452-464.	1.3	2
191	When Alterations in Social Cognition Meet Subjective Complaints in Autism Spectrum Disorder: Evaluation With the "ClaCoS―Battery. Frontiers in Psychiatry, 2021, 12, 643551.	2.6	2
192	Presynaptic Regulation of Dopamine Release in Striatal Compartments and Functional Heterogeneity of the Matrix. Advances in Behavioral Biology, 1994, , 411-419.	0.2	1
193	The Use of Bayesian Networks for Subgrouping Heterogeneous Diseases. Lecture Notes in Computer Science, 2005, , 1140-1148.	1.3	Ο
194	AUTISTIC TRAITS AND DEVELOPMENTAL MARKERS IN ADULT ONSET SCHIZOPHRENIA. Schizophrenia Research, 2010, 117, 139.	2.0	0
195	Poster #260 IMAGING-GENETIC STUDY OF COMT EFFECT ON CORTICAL MORPHOLOGY IN A LARGE SAMPLE OF HEALTHY SUBJECTS. Schizophrenia Research, 2012, 136, S279-S280.	2.0	Ο
196	Thérèse LempérièreÂ: ses travaux sur les psychotropes et perspectives actuelles. Annales Medico-Psychologiques, 2015, 173, 799-803.	0.4	0
197	S118. CAN THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) DIFFERENTIATE REFRACTORY FROM NON-REFRACTORY SCHIZOPHRENIA? A FACTOR ANALYTIC INVESTIGATION BASED ON DATA FROM THE PATTERN COHORT STUDY. Schizophrenia Bulletin, 2018, 44, S371-S371.	4.3	0
198	16.3 METHYLOMIC CHANGES OF OXIDATIVE STRESS REGULATION, AXON GUIDANCE AND INFLAMMATORY PATHWAYS DURING CONVERSION TO PSYCHOSIS. Schizophrenia Bulletin, 2018, 44, S26-S26.	4.3	0

#	Article	IF	CITATIONS
199	M51 CONVERGENT METHYLOMIC SIGNATURE OF CANNABIS EXPOSURE DURING ADOLESCENCE IN HUMAN BLOOD SAMPLES AND RAT PREFRONTAL AREA. European Neuropsychopharmacology, 2019, 29, S193.	0.7	0
200	O6.5. INVESTIGATING VARIABLES FROM THE NAPLS RISK CALCULATOR FOR PSYCHOSIS IN THE EU-GEI HIGH RISK STUDY. Schizophrenia Bulletin, 2019, 45, S177-S178.	4.3	0
201	S175. CLINICAL OUTCOMES IN PEOPLE AT HIGH RISK FOR PSYCHOSIS RELATED TO INTERACTIONS BETWEEN POLYGENIC RISK SCORES AND CHILDHOOD ADVERSITY. Schizophrenia Bulletin, 2020, 46, S104-S104.	4.3	0
202	Schizophrénies : actualités étiopathogéniques et cliniques. Bulletin De L'Academie Nationale De Medecine, 2005, 189, 935-947.	0.0	0
203	Involvement of NMDA Receptors in the Presynaptic Regulation of Dopamine Release in Striosome-and Matrix-enriched Areas of the Rat Striatum. , 1991, , 107-108.		0
204	Chapitre 12. Addiction au cannabis et troubles psychiatriques. , 2014, , 207-221.		0
205	État mental à haut risque de transition psychotique. , 2019, , 167-171.		0
206	Chapitre 5. «ÂModes d'entrée»Â: desÂprodromes auÂpremier épisode psychotique. , 2015, , 67-86.		0
207	Chapitre 8. Marqueurs moléculaires etÂbiologiques. , 2015, , 125-142.		0
208	Chapitre 7. Troubles cognitifs précoces dansÂlaÂpsychose débutante. , 2015, , 109-124.		0
209	Chapitre 4. Modèles physiopathologiquesÂ: modèle neurodéveloppemental, maturation cérébrale et«ÂdoubleÂhit». , 2015, , 53-66.		0
210	Caregiving-related experiences associated with depression severity and its symptomatology among caregivers of individuals with a severe mental disorder: an online cross-sectional study. European Archives of Psychiatry and Clinical Neuroscience, 0, , .	3.2	0